Planning benchmark study for SBRT of early stage NSCLC
Standard
Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy. / Moustakis, Christos; Blanck, Oliver; Ebrahimi Tazehmahalleh, Fatemeh; Ka Heng Chan, Mark; Ernst, Iris; Krieger, Thomas; Duma, Marciana-Nona; Oechsner, Markus; Ganswindt, Ute; Heinz, Christian; Alheit, Horst; Blank, Hilbert; Nestle, Ursula; Wiehle, Rolf; Kornhuber, Christine; Ostheimer, Christian; Petersen, Cordula; Pollul, Gerhard; Baus, Wolfgang; Altenstein, Georg; Beckers, Eric; Jurianz, Katrin; Sterzing, Florian; Kretschmer, Matthias; Seegenschmiedt, Heinrich; Maass, Torsten; Droege, Stefan; Wolf, Ulrich; Schoeffler, Juergen; Haverkamp, Uwe; Eich, Hans Theodor; Guckenberger, Matthias.
in: STRAHLENTHER ONKOL, Jahrgang 193, Nr. 10, 10.2017, S. 780-790.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Planning benchmark study for SBRT of early stage NSCLC
T2 - Results of the DEGRO Working Group Stereotactic Radiotherapy
AU - Moustakis, Christos
AU - Blanck, Oliver
AU - Ebrahimi Tazehmahalleh, Fatemeh
AU - Ka Heng Chan, Mark
AU - Ernst, Iris
AU - Krieger, Thomas
AU - Duma, Marciana-Nona
AU - Oechsner, Markus
AU - Ganswindt, Ute
AU - Heinz, Christian
AU - Alheit, Horst
AU - Blank, Hilbert
AU - Nestle, Ursula
AU - Wiehle, Rolf
AU - Kornhuber, Christine
AU - Ostheimer, Christian
AU - Petersen, Cordula
AU - Pollul, Gerhard
AU - Baus, Wolfgang
AU - Altenstein, Georg
AU - Beckers, Eric
AU - Jurianz, Katrin
AU - Sterzing, Florian
AU - Kretschmer, Matthias
AU - Seegenschmiedt, Heinrich
AU - Maass, Torsten
AU - Droege, Stefan
AU - Wolf, Ulrich
AU - Schoeffler, Juergen
AU - Haverkamp, Uwe
AU - Eich, Hans Theodor
AU - Guckenberger, Matthias
PY - 2017/10
Y1 - 2017/10
N2 - PURPOSE: The aim was to evaluate stereotactic body radiation therapy (SBRT) treatment planning variability for early stage nonsmall cell lung cancer (NSCLC) with respect to the published guidelines of the Stereotactic Radiotherapy Working Group of the German Society for Radiation Oncology (DEGRO).MATERIALS AND METHODS: Planning computed tomography (CT) scan and the structure sets (planning target volume, PTV; organs at risk, OARs) of 3 patients with early stage NSCLC were sent to 22 radiotherapy departments with SBRT experience: each department was asked to prepare a treatment plan according to the DEGRO guidelines. The prescription dose was 3 fractions of 15 Gy to the 65% isodose.RESULTS: In all, 87 plans were generated: 36 used intensity-modulated arc therapy (IMAT), 21 used three-dimensional conformal radiation therapy (3DCRT), 6 used static field intensity-modulated radiation therapy (SF-IMRT), 9 used helical radiotherapy and 15 used robotic radiosurgery. PTV dose coverage and simultaneously kept OARs doses were within the clinical limits published in the DEGRO guidelines. However, mean PTV dose (mean 58.0 Gy, range 52.8-66.4 Gy) and dose conformity indices (mean 0.75, range 0.60-1.00) varied between institutions and techniques (p ≤ 0.02). OARs doses varied substantially between institutions, but appeared to be technique independent (p = 0.21).CONCLUSION: All studied treatment techniques are well suited for SBRT of early stage NSCLC according to the DEGRO guidelines. Homogenization of SBRT practice in Germany is possible through the guidelines; however, detailed treatment plan characteristics varied between techniques and institutions and further homogenization is warranted in future studies and recommendations. Optimized treatment planning should always follow the ALARA (as low as reasonably achievable) principle.
AB - PURPOSE: The aim was to evaluate stereotactic body radiation therapy (SBRT) treatment planning variability for early stage nonsmall cell lung cancer (NSCLC) with respect to the published guidelines of the Stereotactic Radiotherapy Working Group of the German Society for Radiation Oncology (DEGRO).MATERIALS AND METHODS: Planning computed tomography (CT) scan and the structure sets (planning target volume, PTV; organs at risk, OARs) of 3 patients with early stage NSCLC were sent to 22 radiotherapy departments with SBRT experience: each department was asked to prepare a treatment plan according to the DEGRO guidelines. The prescription dose was 3 fractions of 15 Gy to the 65% isodose.RESULTS: In all, 87 plans were generated: 36 used intensity-modulated arc therapy (IMAT), 21 used three-dimensional conformal radiation therapy (3DCRT), 6 used static field intensity-modulated radiation therapy (SF-IMRT), 9 used helical radiotherapy and 15 used robotic radiosurgery. PTV dose coverage and simultaneously kept OARs doses were within the clinical limits published in the DEGRO guidelines. However, mean PTV dose (mean 58.0 Gy, range 52.8-66.4 Gy) and dose conformity indices (mean 0.75, range 0.60-1.00) varied between institutions and techniques (p ≤ 0.02). OARs doses varied substantially between institutions, but appeared to be technique independent (p = 0.21).CONCLUSION: All studied treatment techniques are well suited for SBRT of early stage NSCLC according to the DEGRO guidelines. Homogenization of SBRT practice in Germany is possible through the guidelines; however, detailed treatment plan characteristics varied between techniques and institutions and further homogenization is warranted in future studies and recommendations. Optimized treatment planning should always follow the ALARA (as low as reasonably achievable) principle.
KW - Benchmarking
KW - Carcinoma, Non-Small-Cell Lung
KW - Germany
KW - Guideline Adherence
KW - Humans
KW - Lung Neoplasms
KW - Neoplasm Staging
KW - Prevalence
KW - Radiosurgery
KW - Radiotherapy Dosage
KW - Radiotherapy Planning, Computer-Assisted
KW - Reproducibility of Results
KW - Sensitivity and Specificity
KW - Treatment Outcome
KW - Journal Article
KW - Multicenter Study
U2 - 10.1007/s00066-017-1151-8
DO - 10.1007/s00066-017-1151-8
M3 - SCORING: Journal article
C2 - 28567503
VL - 193
SP - 780
EP - 790
JO - STRAHLENTHER ONKOL
JF - STRAHLENTHER ONKOL
SN - 0179-7158
IS - 10
ER -